Coherus Biosciences (CHRS) PT Raised to $14 at Citi
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.19 -0.83%
Rating Summary:
11 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 20
Rating Summary:
11 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 20
Join SI Premium – FREE
Citi analyst Yigal Nochomovitz raised the price target on Coherus Biosciences (NASDAQ: CHRS) to $14.00 (from $13.00) while maintaining a Buy rating.
You May Also Be Interested In
- JPMorgan Upgrades Hyundai Marine and Fire Insurance (001450:KS) to Neutral
- SM Prime Holdings, Inc (SMPH:PM) (SPHXF) PT Lowered to PHP21 at JPMorgan
- Kweichow Moutai Co Ltd (600519:CH) PT Lowered to RMB1,400 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
